Keros Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $244.1 | $3.5 | $0.2 | $0.0 | $20.1 |
| Operating income | $67.6 | -$210.8 | -$169.9 | -$114.8 | -$56.4 |
| Net income | $87.0 | -$187.4 | -$153.0 | -$104.7 | -$58.7 |
| Cash Flow Statement | |||||
| Free cash flow | $106.0 | -$162.8 | -$127.0 | -$71.3 | -$63.2 |
| Share repurchases | $375.0 | $0.0 | — | — | — |
Shares outstanding 19.8M · Free float 70.5%
Annual filing data through FY ended December 31, 2025; float as of October 3, 2026.